The startup develops cardiac devices for the epicardial ablation of atrial and ventricular tissue, enabling minimally invasive procedures. Their technology allows electrophysiologists to precisely target and ablate diseased cardiac tissue, facilitating the restoration of normal heart rhythm.
Funding
$4.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current methods for cardiac ablation, which eliminate tissue causing heart rhythm abnormalities, can be invasive and lack precision, potentially damaging surrounding healthy tissue. Achieving effective ablation through thick tissue, warm blood flow, and insulating fat on the heart's surface remains a challenge.
Solution
Corfigo Inc. offers the HeartPad® "XLT" Cryoablation System, a cryothermal ablation technology designed for minimally invasive surgical and percutaneous catheter ablation of cardiac tissue from an epicardial location. The system utilizes potent cryothermal energy and a sophisticated delivery system to achieve dense and uniform therapeutic ablation of diseased cardiac tissue. The HeartPad® is designed to protect adjacent structures from unintentional ablation injury while overcoming barriers such as thick tissue, warm cardiac blood flow, and insulating fat tissue on the outer heart surface. Cryoablation may also offer better preservation of extracellular architecture and reduced inflammation compared to other thermal energy sources.
Target Audience
The primary target audience includes electrophysiologists and cardiac surgeons specializing in the treatment of atrial and ventricular arrhythmias.
Features
- Cryoablation technology for ablating cardiac tissue from the outer surface of the heart (epicardial ablation)
- Designed for both minimally invasive surgical (MIS) and percutaneous catheter ablation procedures
- Patented technology utilizes potent cryothermal energy for effective tissue ablation
- Sophisticated delivery system ensures precise targeting of diseased cardiac tissue
- Designed to protect adjacent structures from unintentional ablation injury
- Aims to achieve dense and uniform therapeutic ablation, even through thick tissue, warm blood flow, and insulating fat
- Cryoablation may be associated with better preservation of extracellular architecture and less inflammation compared with other thermal energy sources